The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study
W Hoefsloot, J Van Ingen, C Andrejak… - European …, 2013 - Eur Respiratory Soc
A significant knowledge gap exists concerning the geographical distribution of nontuberculous
mycobacteria (NTM) isolation worldwide. To provide a snapshot of NTM species …
mycobacteria (NTM) isolation worldwide. To provide a snapshot of NTM species …
Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands
J van Ingen, SA Bendien, WCM de Lange, W Hoefsloot… - Thorax, 2009 - thorax.bmj.com
Background: The frequency of clinical isolation of non-tuberculous mycobacteria (NTM) in the
Netherlands is increasing, but its clinical relevance is often uncertain. Objective: To assess …
Netherlands is increasing, but its clinical relevance is often uncertain. Objective: To assess …
[PDF][PDF] Systematic review of quantitative clinical gait analysis in patients with dementia
MB van Iersel, W Hoefsloot, M Munneke… - … fur Gerontologie und …, 2004 - repository.ubn.ru.nl
Introduction Diminished mobility often accompanies dementia and has a great impact on
independence and quality of life. New treatment strategies for dementia are emerging, but the …
independence and quality of life. New treatment strategies for dementia are emerging, but the …
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
…, V Gruslys, G Gualano, W Hoefsloot… - European …, 2019 - Eur Respiratory Soc
The World Health Organization (WHO) recommends that countries implement pharmacovigilance
and collect information on active drug safety monitoring (aDSM) and management of …
and collect information on active drug safety monitoring (aDSM) and management of …
Relative contributions of central and peripheral factors to fatigue during a maximal sustained effort
ML Schillings, W Hoefsloot, DF Stegeman… - European journal of …, 2003 - Springer
Local muscle fatigue can originate from both peripheral and central factors. The relative
contribution of these factors in the course of a fatiguing contraction in 20 healthy subjects was …
contribution of these factors in the course of a fatiguing contraction in 20 healthy subjects was …
[HTML][HTML] High mortality in patients with Mycobacterium avium complex lung disease: a systematic review
R Diel, M Lipman, W Hoefsloot - BMC infectious diseases, 2018 - Springer
Background The incidence of nontuberculous mycobacterial (NTM) pulmonary disease
caused by Mycobacterium avium complex (MAC) in apparently immune-competent people is …
caused by Mycobacterium avium complex (MAC) in apparently immune-competent people is …
[HTML][HTML] Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study
…, E Abbink, M Reijers, Q de Mast, W Hoefsloot… - PLoS …, 2021 - journals.plos.org
Objective To describe clinical characteristics, disease course and outcomes in a large and
well-documented cohort of hospitalized COVID-19 patients in the Netherlands. Methods We …
well-documented cohort of hospitalized COVID-19 patients in the Netherlands. Methods We …
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial
…, M van den Heuvel, W Hoefsloot… - The Lancet …, 2021 - thelancet.com
Background The major complication of COVID-19 is hypoxaemic respiratory failure from
capillary leak and alveolar oedema. Experimental and early clinical data suggest that the …
capillary leak and alveolar oedema. Experimental and early clinical data suggest that the …
Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19
…, T Frenzel, MHE Reijers, W Hoefsloot… - The Journal of …, 2021 - academic.oup.com
The clinical spectrum of COVID-19 varies and the differences in host response characterizing
this variation have not been fully elucidated. COVID-19 disease severity correlates with an …
this variation have not been fully elucidated. COVID-19 disease severity correlates with an …
Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence
J Van Ingen, BE Ferro, W Hoefsloot… - Expert review of anti …, 2013 - Taylor & Francis
Pulmonary disease (PD) caused by nontuberculous mycobacteria is an emerging infection
mainly in countries where the incidence of tuberculosis is in decline. It affects an elderly …
mainly in countries where the incidence of tuberculosis is in decline. It affects an elderly …